Michael Scott Bumby
Chief Financial OfficerDr. Michael Scott Bumby, DVM, MBA, also known as Mike, is Chief Financial Officer of XORTX Therapeutics Inc. from December 18, 2024. Dr. Bumby served as Independent Director at MediPharm Labs Corp. since April 1, 2023 until June 16, 2025 and serves as its Director since January 01, 2026. He had been the Chief Financial Officer of VIVO Cannabis Inc. since December 1, 2017 until April 2023 and served as its Secretary since July 2021 until December 2021. He served as Director at VIVO Cannabis Inc. since July 5, 2021 until December 17, 2021. Dr. Bumby has extensive public company Chief Financial Officer, global pharmaceutical and M&A experience. He served as Chief Financial Officer at Merus Labs International Inc. since July 1, 2016 until November 2017. He was instrumental in strengthening financial planning and analysis, business development, internal controls and budget management and was part of the strategic review core team that facilitated the acquisition of Merus by Norgine B.V. in July 2017. Dr. Bumby has experience in the pharmaceutical industry. He served as the Chief Financial Officer at Acerus Pharmaceuticals Corporation since August 3, 2015 until June 1, 2016. He served as the Chief Financial Officer of Antibe Therapeutics Inc. since November 2012 until September 2015. He served as a Vice President of Business Development at Stronach Group, managing the personal assets of Dr. Frank Stronach. Previously, he served as a Director of Mergers & Acquisitions at Eli Lilly in Indianapolis, Indiana, where he gained extensive experience in asset in-licensing, out-licensing, development Partnering and commercialization Partnering. Dr. Bumby has also served as the Chief Financial Officer of a subsidiary of Eli Lilly, in Prague, Czech Republic, coordinated Eli Lilly's international financial operations, managed Eli Lilly Canada Inc.'s operational expenditures and capital planning, forecasting and reporting processes and managed research and development finances for one of Eli Lilly's Canadian subsidiaries. Dr. Bumby had a certain year career at Eli Lilly, including Corporate Finance & Investment Banking at Lilly's global Headquarters in Indianapolis leading international business development activities for early and late stage assets. He earned a six sigma black belt for his leadership of multiple international projects while at Eli Lilly. He served as the Vice-President Operations of a Toronto-based business-to-business start-up, an equine veterinarian, a co-Founder of a world class equine surgical facility and a small animal veterinarian. Dr. Bumby received Natural Sciences and Engineering Research Council of Canada Scholarship to conduct research to characterize canine cerebrospinal immuno globulins and he holds a Doctor of Veterinary Medicine from the University of Guelph and MBA from the University of Toronto.
公司职务
- 公司名称XORTX Therapeutics Inc.股票代码XRTX职务Chief Financial Officer共事同僚
- AWAllen Warren DavidoffFounder, Co-CEO, President & Director
- SHStephen HaworthChief Medical Officer
- SEStacy EvansChief Business Officer
- MGMika GrassoCo-CEO & Director
- RJRichard J. JohnsonMember of Clinical Advisory Board
- PBPetter BjornstadMember of Clinical Advisory Board
- ARAnjay RastogiMember of the Clinical Advisory Board
